---
schema_version: "secwatch.filing_event.v1"
accession: "0001835268-26-000019"
form_type: "8-K"
ticker: "CNTB"
cik: "0001835268"
company_name: "Connect Biopharma Holdings Ltd"
filed_at: "2026-05-12T13:02:24+00:00"
generated_at: "2026-05-12T13:03:45.164953+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Connect Biopharma reports Q1 net loss $19.4M; Phase 2 studies on track, topline data mid-2026

## Summary
- Net loss $19.4M ($0.34 loss per share) vs $10.3M loss ($0.19 per share) in Q1 2025.
- Cash $46.0M as of March 31, 2026; expects funding into H2 2027.
- Phase 2 Seabreeze STAT asthma/COPD studies continuing after DMC review; topline data expected mid-2026.
- Completed $20.2M private placement led by Panacea Venture on March 31, 2026.
- R&D expense $15.0M (up from $6.6M) due to rademikibart development; license revenue $0.2M from Simcere agreement.

## SEC filing metadata
- accession: 0001835268-26-000019
- form_type: 8-K
- ticker: CNTB
- cik: 0001835268
- company_name: Connect Biopharma Holdings Ltd
- filed_at: 2026-05-12T13:02:24+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835268/000183526826000019/0001835268-26-000019-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835268/000183526826000019/cntb-20260512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001835268-26-000019
- JSON: https://secwatch.observer/filing/0001835268-26-000019.json
- Plain text: https://secwatch.observer/filing/0001835268-26-000019.txt

## Key facts
- Earnings Releases
  Connect Biopharma Holdings Ltd reported the three months ended March 31, 2026 results: revenue $0.2 million, net income $19.4 million, EPS ($0.34) per share.
  - Period: the three months ended March 31, 2026
  - Revenue: $0.2 million
  - Net income: $19.4 million
  - EPS: ($0.34) per share
  - Result: reported results
  source text: its cash and investments will be sufficient to fund operations into the second half of 2027. • License and collaboration revenues for the three months ended March 31, 2026 were $0.2 million related to the upfront license fee under the license agreement with Simcere. There were no license and collaboration revenues for the three months ended March 31, 2025. As a part
  evidence_url: https://www.sec.gov/Archives/edgar/data/1835268/000183526826000019/0001835268-26-000019-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.